Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Latest filing published 02 Mar 2023 for Karyopharm Therapeutics Inc.. Read the official filing
Filing timeline
BuySaleStephen Mitchener
Insider track record
Disclosed buys
0
Disclosed sells
2
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Stephen Mitchener: trading record in brief
Stephen Mitchener, listed as chief executive, appears in our data through filings on Karyopharm Therapeutics Inc. shares, published by SEC (Form 4). Between 30 May 2021 and 28 February 2023, the trades on record add up to 6 filings.
No open-market purchase appears, only 2 sales worth €6,967. The rest of the record consists of 3 share grants and 1 option exercise.
The newest entry dates from 2 March 2023: a share grant, in Karyopharm Therapeutics Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Stephen Mitchener
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
60,000 shares0Common StockSEC:0001209191-23-014869:0
20,000 shares0Common StockSEC:0001209191-22-048397:0
47,250 shares0Common StockSEC:0001209191-22-014623:0
499 shares@ US$6.6942.3% of flowCommon StockSEC:0001209191-21-067954:0
528 shares@ US$9.2957.7% of flowCommon StockSEC:0000899243-21-021767:0
1,500 sharesCommon StockSEC:0000899243-21-021292:0
6 of 6 declarations
